OR WAIT null SECS
March 15, 2024
Article
Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.
March 13, 2024
The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.
March 11, 2024
Baseline kidney function, AKD severity, and post-AKD kidney function were identified as important factors for predicting outcomes in patients with acute kidney injury requiring dialysis.
March 08, 2024
Results of the systematic review point to significant evidence gaps in most cardiovascular risk management interventions for patients with CKD, especially those with stages 4 to 5.
March 05, 2024
Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Our February 2024 month in review spotlights news in IgAN identification and management as well as recent research about various factors impacting renal care outcomes in different patient populations.
February 16, 2024
Nearly 30% of patients were receiving potentially inappropriately prescribed medications at the start of the study and more than 20% were still receiving these medications 1 year later.
February 08, 2024
Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.
February 06, 2024
Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
January 31, 2024
Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
